美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

TuHURA Biosciences, Inc.

1.56

-0.0800-4.88%

盤後：1.600.0400+2.56%17:54 EST

成交量：37.17萬

成交額：58.36萬

市值：9,472.40萬

市盈率：-2.35

高：1.65

開：1.61

低：1.47

收：1.64

52周最高：4.44

52周最低：0.4100

股本：6,072.05萬

流通股本：5,428.64萬

量比：0.31

換手率：0.68%

股息：- -

股息率：- -

每股收益(TTM):-0.6627

每股收益(LYR):-1.2136

淨資產收益率：-418.06%

總資產收益率：-60.16%

市淨率：5.74

市盈率(LYR):-1.29

資料載入中...

總覽公司新聞資訊公告

Tuhura Biosciences, Inc.盤中異動早盤快速上漲8.18%報1.20美元

Tuhura Biosciences, Inc.盤中異動快速下跌5.26%報1.26美元

TuHURA提交TBS-2025治療血液類癌症的新藥臨床試驗申請

TuHURA生物科學公司計劃於2026年第二季度啓動針對NPM1突變型復發/難治性急性髓系白血病的二期研究，初步一期結果將於2026年第三季度公布

Tuhura Biosciences, Inc.盤中異動快速下挫5.55%

TuHURA Biosciences獲FDA孤兒藥認定 IFX-2.0有望治療IIb至IV期皮膚黑色素瘤

Tuhura Biosciences, Inc.盤中異動股價大漲6.74%

Tuhura Biosciences發布Kintara的應急價值權（CVR），因Kintara的Rem-001達到了主要安全目標，實現合同里程碑

BUZZ-1560 萬美元直接股票交易後，TuHURA 生物科學公司股價暴跌

Tuhura Biosciences展示數據顯示，Delta阿片受體（Dor）作為克服對免疫檢查點抑制劑獲得性耐藥的新靶點，亮相第57屆ASH年會暨博覽會

Tuhura Biosciences Inc申請最高2.5億美元的混合貨架註冊

Tuhura Biosciences Inc：與H.C. Wainwright簽訂Atm協議以出售高達5000萬美元的普通股

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/HURA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":1.56,"timestamp":1772744400000,"preClose":1.64,"halted":0,"volume":371658,"hourTrading":{"tag":"盘后","latestPrice":1.6,"preClose":1.56,"latestTime":"17:54 EST","volume":1450,"amount":2268.388555,"timestamp":1772751244499,"change":0.04,"changeRate":0.025641,"amplitude":0.03141},"delay":0,"changeRate":-0.04878048780487796,"floatShares":54286373,"shares":60720508,"eps":-0.662671,"marketStatus":"盤後交易","change":-0.08,"latestTime":"03-05 18:35:09 EST","open":1.61,"high":1.65,"low":1.47,"amount":583561.967793,"amplitude":0.109756,"askPrice":1.65,"askSize":367,"bidPrice":1.56,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.662671,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1772758800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.64,"preHourTrading":{"tag":"盘前","latestPrice":1.63,"preClose":1.64,"latestTime":"09:01 EST","volume":114,"amount":187.2615984,"timestamp":1772719279242,"change":-0.01,"changeRate":-0.006098,"amplitude":0.012195},"postHourTrading":{"tag":"盘后","latestPrice":1.6,"preClose":1.56,"latestTime":"17:54 EST","volume":1450,"amount":2268.388555,"timestamp":1772751244499,"change":0.04,"changeRate":0.025641,"amplitude":0.03141},"volumeRatio":0.305036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":54286373,"roa":"-60.16%","roe":"-418.06%","lyrEps":-1.213628,"volumeRatio":0.305036,"shares":60720508,"dividePrice":0,"high":1.65,"amplitude":0.109756,"preClose":1.64,"low":1.47,"week52Low":0.41,"pbRate":"5.74","week52High":4.44,"institutionHeld":0,"latestPrice":1.56,"committee":-0.571734,"eps":-0.662671,"divideRate":0,"volume":371658,"delay":0,"ttmEps":-0.662671,"open":1.61,"prevYearClose":0.7567,"prevWeekClose":1.67,"prevMonthClose":1.67,"prevQuarterClose":0.7567},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-14","symbol":"HURA","fiscalQuarterEnding":"2025/09","expectedEps":-0.15,"name":null,"time":"盤前","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-08-14","symbol":"HURA","fiscalQuarterEnding":"2025/06","expectedEps":-0.14,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2025-05-15","symbol":"HURA","fiscalQuarterEnding":"2025/03","expectedEps":-0.13,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-03-31","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"HURA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-1.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1755234000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2026-03-04","current":-2.354109,"percent":0.829851,"low":-15.284879,"twenty":-8.340296,"median":-5.033917,"eighty":-3.465457,"high":-0.912265,"avg":-5.845623,"sd":3.014506,"marketCap":94116787},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-09","current":-7.917237,"twenty":-10.46885,"median":-8.350494,"eighty":-7.05932,"marketCap":171663960},{"date":"2025-05-16","current":-7.735926,"twenty":-10.401955,"median":-8.271427,"eighty":-7.082258,"marketCap":167732724},{"date":"2025-05-23","current":-5.593729,"twenty":-10.356677,"median":-8.259713,"eighty":-7.009861,"marketCap":131477994},{"date":"2025-05-30","current":-5.909654,"twenty":-10.322004,"median":-8.210864,"eighty":-6.792598,"marketCap":138903659},{"date":"2025-06-06","current":-5.370723,"twenty":-10.312959,"median":-8.038111,"eighty":-6.609295,"marketCap":126236344},{"date":"2025-06-13","current":-4.86896,"twenty":-10.273819,"median":-7.961523,"eighty":-5.965405,"marketCap":114442640},{"date":"2025-06-20","current":-5.01763,"twenty":-10.268299,"median":-7.907165,"eighty":-5.77585,"marketCap":117937071},{"date":"2025-06-27","current":-4.255694,"twenty":-10.254133,"median":-7.8568,"eighty":-5.590128,"marketCap":100028109},{"date":"2025-07-03","current":-4.911411,"twenty":-10.238281,"median":-7.856432,"eighty":-5.456208,"marketCap":115440443},{"date":"2025-07-11","current":-4.990628,"twenty":-10.201312,"median":-7.766145,"eighty":-5.256797,"marketCap":117302386},{"date":"2025-07-18","current":-5.010432,"twenty":-10.182292,"median":-7.688203,"eighty":-5.039996,"marketCap":117767871},{"date":"2025-07-25","current":-5.624358,"twenty":-10.127376,"median":-7.668851,"eighty":-5.052895,"marketCap":132197927},{"date":"2025-08-01","current":-4.911411,"twenty":-10.049579,"median":-7.615053,"eighty":-5.052895,"marketCap":115440443},{"date":"2025-08-08","current":-4.812391,"twenty":-9.994663,"median":-7.555364,"eighty":-5.037142,"marketCap":113113015},{"date":"2025-08-15","current":-4.975285,"twenty":-9.907714,"median":-7.528032,"eighty":-5.017728,"marketCap":138129515},{"date":"2025-08-22","current":-5.245681,"twenty":-9.861951,"median":-7.477167,"eighty":-5.037142,"marketCap":145636554},{"date":"2025-08-29","current":-5.065417,"twenty":-9.847676,"median":-7.326779,"eighty":-5.052895,"marketCap":140631862},{"date":"2025-09-05","current":-4.560678,"twenty":-9.79276,"median":-7.254296,"eighty":-5.013311,"marketCap":126618722},{"date":"2025-09-12","current":-4.668836,"twenty":-9.696332,"median":-7.110931,"eighty":-4.956091,"marketCap":129621538},{"date":"2025-09-19","current":-4.65081,"twenty":-9.618099,"median":-7.053585,"eighty":-4.911411,"marketCap":129121069},{"date":"2025-09-26","current":-4.416467,"twenty":-9.555338,"median":-6.959639,"eighty":-4.875184,"marketCap":122614968},{"date":"2025-10-03","current":-4.704889,"twenty":-9.532456,"median":-6.792598,"eighty":-4.824615,"marketCap":130622476},{"date":"2025-10-10","current":-4.65081,"twenty":-9.500422,"median":-6.659051,"eighty":-4.759515,"marketCap":129121069},{"date":"2025-10-17","current":-4.326335,"twenty":-9.445506,"median":-6.451252,"eighty":-4.704889,"marketCap":120112622},{"date":"2025-10-24","current":-4.019886,"twenty":-9.386014,"median":-6.151486,"eighty":-4.692197,"marketCap":111604644},{"date":"2025-10-31","current":-4.470546,"twenty":-9.301564,"median":-5.965405,"eighty":-4.668836,"marketCap":124116376},{"date":"2025-11-07","current":-4.416467,"twenty":-9.208999,"median":-5.850391,"eighty":-4.621968,"marketCap":122614968},{"date":"2025-11-14","current":-3.677385,"twenty":-9.18008,"median":-5.798151,"eighty":-4.596731,"marketCap":102095729},{"date":"2025-11-21","current":-2.774116,"twenty":-9.039762,"median":-5.662432,"eighty":-4.565822,"marketCap":81244064},{"date":"2025-11-28","current":-3.500461,"twenty":-8.84257,"median":-5.63426,"eighty":-4.556086,"marketCap":102516170},{"date":"2025-12-05","current":-3.465457,"twenty":-8.730961,"median":-5.593729,"eighty":-4.544729,"marketCap":101491008},{"date":"2025-12-12","current":-1.811489,"twenty":-8.705462,"median":-5.561421,"eighty":-4.506599,"marketCap":53052117},{"date":"2025-12-19","current":-1.552105,"twenty":-8.587093,"median":-5.505534,"eighty":-4.470546,"marketCap":45455669},{"date":"2025-12-26","current":-1.707387,"twenty":-8.521606,"median":-5.445058,"eighty":-4.45252,"marketCap":50003338},{"date":"2026-01-02","current":-1.568888,"twenty":-8.50549,"median":-5.407919,"eighty":-4.416467,"marketCap":45947208},{"date":"2026-01-09","current":-1.564327,"twenty":-8.469228,"median":-5.371294,"eighty":-4.409256,"marketCap":45813623},{"date":"2026-01-16","current":-1.57656,"twenty":-8.46117,"median":-5.317787,"eighty":-4.331172,"marketCap":46171874},{"date":"2026-01-23","current":-1.408413,"twenty":-8.46117,"median":-5.267885,"eighty":-4.319125,"marketCap":41247441},{"date":"2026-01-30","current":-1.163138,"twenty":-8.430269,"median":-5.249422,"eighty":-4.265631,"marketCap":34064204},{"date":"2026-02-06","current":-0.912265,"twenty":-8.395844,"median":-5.227655,"eighty":-4.145319,"marketCap":26717023},{"date":"2026-02-13","current":-2.881928,"twenty":-8.370916,"median":-5.188669,"eighty":-4.09774,"marketCap":84401506},{"date":"2026-02-20","current":-2.301396,"twenty":-8.352484,"median":-5.119354,"eighty":-3.87886,"marketCap":67399763},{"date":"2026-02-27","current":-3.358794,"twenty":-8.340447,"median":-5.054798,"eighty":-3.490101,"marketCap":98367222},{"date":"2026-03-04","current":-3.213661,"twenty":-8.340296,"median":-5.033917,"eighty":-3.465457,"marketCap":94116787}],"updateTime":1772753709458},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613246866","title":"Tuhura Biosciences, Inc.盤中異動 早盤快速上漲8.18%報1.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613246866","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613246866?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 22:31","pubTimestamp":1771597903,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日22时31分，Tuhura Biosciences, Inc.股票出现异动，股价大幅上涨8.18%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220223143a70d9787&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220223143a70d9787&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2612925624","title":"Tuhura Biosciences, Inc.盤中異動 快速下跌5.26%報1.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612925624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612925624?lang=zh_tw&edition=fundamental","pubTime":"2026-02-17 23:30","pubTimestamp":1771342229,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日23时30分，Tuhura Biosciences, Inc.股票出现波动，股价大幅跳水5.26%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。其相关个股中，Polaryx Therapeutics, Inc.、Quoin Pharmaceuticals Ltd、Eyepoint, Inc.涨幅较大，Ernexa Therapeutics Inc.、Moolec Science Sa、Quince Therapeutics, Inc.较为活跃，换手率分别为75.47%、58.89%、50.22%，振幅较大的相关个股有Quoin Pharmaceuticals Ltd、Polaryx Therapeutics, Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为27.14%、26.97%、25.79%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021723302995415b89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021723302995415b89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"1159427520","title":"TuHURA提交TBS-2025治療血液類癌症的新藥臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1159427520","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159427520?lang=zh_tw&edition=fundamental","pubTime":"2026-02-17 20:50","pubTimestamp":1771332610,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. 已正式向监管机构递交了其候选药物TBS-2025的研究性新药申请，该药物旨在针对血液相关癌症开展临床治疗研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"1186309065","title":"TuHURA生物科學公司計劃於2026年第二季度啓動針對NPM1突變型復發/難治性急性髓系白血病的二期研究，初步一期結果將於2026年第三季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1186309065","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186309065?lang=zh_tw&edition=fundamental","pubTime":"2026-02-17 20:48","pubTimestamp":1771332495,"startTime":"0","endTime":"0","summary":"TuHURA生物科学公司近日披露其研发管线的最新进展。该公司计划于2026年第二季度正式启动针对NPM1突变型复发/难治性急性髓系白血病的二期临床研究。这项研究旨在评估其在研疗法对该特定患者群体的安全性与有效性。\n与此同时，该药物一期临床研究的初步数据预计将于2026年第三季度揭晓。这些早期结果将为后续临床开发提供重要依据，并有助于优化二期试验的设计方案。公司表示，将严格遵循监管要求推进研究进程，力求为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2608977807","title":"Tuhura Biosciences, Inc.盤中異動 快速下挫5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608977807","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608977807?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 22:33","pubTimestamp":1770129200,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日22时33分，Tuhura Biosciences, Inc.股票出现波动，股价快速跳水5.55%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。该公司的个性化癌症候选疫苗 IFx-2.0 旨在克服对检查点抑制剂的主要耐药性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020322332197a4b21c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020322332197a4b21c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"1169978766","title":"TuHURA Biosciences獲FDA孤兒藥認定 IFX-2.0有望治療IIb至IV期皮膚黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1169978766","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169978766?lang=zh_tw&edition=fundamental","pubTime":"2026-02-02 20:45","pubTimestamp":1770036316,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. (以下简称TuHURA) 宣布，其研发的候选药物IFX-2.0已获得美国食品药品监督管理局（FDA）授予的孤儿药资格认定，适应症为IIb期至IV期皮肤黑色素瘤。\n孤儿药认定旨在鼓励针对罕见病的新药研发。获得该认定意味着IFX-2.0在针对这一特定阶段的黑色素瘤治疗方面，有望在药物开发及后续商业化进程中享受一系列政策支持，包括临床试验费用税收抵免、FDA用户费减免以及药物获批后七年的市场独占权。\n此次认定标志着IFX-2.0在治疗晚期皮肤黑色素瘤的研发道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2601937463","title":"Tuhura Biosciences, Inc.盤中異動 股價大漲6.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601937463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601937463?lang=zh_tw&edition=fundamental","pubTime":"2026-01-08 04:02","pubTimestamp":1767816142,"startTime":"0","endTime":"0","summary":"北京时间2026年01月08日04时02分，Tuhura Biosciences, Inc.股票出现异动，股价急速上涨6.74%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为3.15%。其相关个股中，Revolution Medicines Inc C/Wts 17/12/2026 、Lexaria Bioscience Corp C/Wts 14/01/2026 、Erasca, Inc.涨幅较大，Cardio Diagnostics Holdings Inc.、Pmgc Holdings Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为1093.70%、682.96%、351.70%，振幅较大的相关个股有Revolution Medicines Inc C/Wts 17/12/2026 、Erasca, Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为202.13%、67.49%、50.85%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108040222a6ffe016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108040222a6ffe016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"1150512948","title":"Tuhura Biosciences發布Kintara的應急價值權（CVR），因Kintara的Rem-001達到了主要安全目標，實現合同里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1150512948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150512948?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 20:50","pubTimestamp":1765803053,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences发布Kintara的应急价值权（CVR），因Kintara的Rem-001达到了主要安全目标，实现合同里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2590340400","title":"BUZZ-1560 萬美元直接股票交易後，TuHURA 生物科學公司股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2590340400","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590340400?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 23:56","pubTimestamp":1765295777,"startTime":"0","endTime":"0","summary":"BUZZ-1560 万美元直接股票交易后，TuHURA 生物科学公司股价暴跌12月9日 - ** 药物开发商TuHURA Biosciences的HURA.O股价暴跌36.9%至1.25美元** HURA 在  签订协议，以每股 1.65 美元的购买价在注册直接发行中出售约 950 万股股票、A 系列认股权证和 B 系列认股权证，募集资金总额为 1560 万美元。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL4S3XF1ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"1183862465","title":"Tuhura Biosciences展示數據顯示，Delta阿片受體（Dor）作為克服對免疫檢查點抑制劑獲得性耐藥的新靶點，亮相第57屆ASH年會暨博覽會","url":"https://stock-news.laohu8.com/highlight/detail?id=1183862465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183862465?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 20:51","pubTimestamp":1765198302,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences展示数据显示，Delta阿片受体（Dor）作为克服对免疫检查点抑制剂获得性耐药的新靶点，亮相第57届ASH年会暨博览会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"1115688327","title":"Tuhura Biosciences Inc申請最高2.5億美元的混合貨架註冊","url":"https://stock-news.laohu8.com/highlight/detail?id=1115688327","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115688327?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 00:31","pubTimestamp":1763569873,"startTime":"0","endTime":"0","summary":"11月4日 - TuHURA Biosciences Inc宣布，已向SEC提交申请，计划进行最高达2.5亿美元的混合货架注册。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"1152480810","title":"Tuhura Biosciences Inc：與H.C. Wainwright簽訂Atm協議以出售高達5000萬美元的普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1152480810","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152480810?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 20:23","pubTimestamp":1762259005,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc：与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}